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Platelet adhesion to the subendothelial matrix and the subse- 
quent aggregation of the activated platelets is a special case 
of intercellular adhesion that is  highly regulated and for 
which multiple, possibly redundant adhesive systems exist. 
The large "adhesive glycoproteins" such as fibrinogen, von 
Willebrand factor, and fibronectin and their receptors, which 
participate  in  platelet adhesion  and aggregation,  are  not 
unique to platelets, and probably serve analogous functions 
in a  variety of cell types and locations.  Thrombospondin 
(TS)/the most abundant protein of platelet alpha-granules, 
has been recognized as a new member of this class of adhe- 
sive glycoproteins.  Whereas  other adhesive glycoproteins 
are contained within alpha-granules and secreted upon plate- 
let activation, they also exist in plasma at high concentra- 
tions.  Hence TS  is the only member of the group that is 
unique to alpha-granules and whose expression in quantity 
at sites of platelet aggregation is absolutely dependent on 
platelet activation. 
Since its discovery in 1971, TS has been thought to have 
a role in platelet aggregation (3, 4). This suspicion has re- 
cently been confirmed by the fnding that both monoclonal 
(14) and polyclonal (22, 37) antibodies against platelet TS can 
block the secondary or secretion-dependent phase of platelet 
aggregation. This result in itself, however,  does not speak 
directly to the mechanism of TS involvement in this complex 
process, since antibodies against fibrinogen (62), fibronectin 
(13), and the platelet glycoprotein IIb/IIIa (43), the receptor 
on platelets for fibrinogen and fibronectin, will all block 
platelet aggregation. Other agents that block aggregation are 
short peptide sequences related either to RGDS,  the cell- 
binding sequence of fibronectin and fibrinogen (21), or to the 
COOH-terminal  segment of the  fibrinogen gamma chain 
(27).  Both interfere with the binding of fibrinogen, fibro- 
nectin (58),  and presumably yon Willebrand factor (61) to 
IIb/IIIa. 
In addition to its localization in platelets and its presumed 
synthesis in megakaryocytes (42), TS has been found, using 
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immunofluorescence localization techniques, in a variety of 
extracellular locations in human tissues including blood ves- 
sel,  muscle,  skin, kidney, and glandular epithelium (64). 
The biosynthesis of TS has been demonstrated in a number 
of normal and transformed cells in culture,  including en- 
dothelial, smooth muscle, and glial cells, type II pneumo- 
cytes, fibroblasts, keratinocytes, and macrophages (1, 25, 26, 
45, 46, 50, 57, 65).  Furthermore, several  cell lines derived 
from malignancies such as HT-1080 fibrosarcoma cells and 
the melanoma lines C32 and G361 also make TS (54, 63). 
This widespread expression of TS and its appearance as a 
component of the extracellular matrix have led to the sugges- 
tion that TS might have a role analogous to that of fibronectin 
and laminin in cell attachment, motility, and perhaps differ- 
entiation. TS does not appear to be an obligatory attachment 
factor for cultured cells such as fibroblasts, smooth muscle 
cells, or endothelial cells. However, Roberts et al. (54) have 
reported that C32 and 13361 melanoma cells attach and spread 
on TS-coated substrates and that attachment and spreading 
are blocked by different TS monoclonal antibodies (mAbs). 
Thus at least some types of cells appear to express receptors 
for TS that can mediate classical attachment and spreading 
functions (62a).  Recently TS has been implicated in the at- 
tachment of P. falciparum-parasitized erythrocytes to mela- 
noma cells, a  model for endothelial cell adherence of in- 
fected red blood cells that express malaria-encoded surface 
antigens (55). 
Modular Structure of Thrombospondin 
Various experimental approaches have suggested that TS, 
like fibronectin, laminin, and other adhesive glycoproteins, 
is a multidomain or modular glycoprotein in which discrete 
regions of relatively stable protein structure contain binding 
sites for the other proteins with which TS interacts. These 
proteins  include several found in the extracellular matrix 
such as fibroncctin (29), heparan sulfate proteoglycans and 
heparin (7,  12, 35, 51), collagen (20, 47), and laminin (31). 
Plasma proteins important in the regulation of thrombosis 
such as fibrinogen (U), plasminogen (31, 59), and histidine- 
rich glycoprotein (38,  60) also interact with TS, and there 
exists preliminary evidence that TS  binds to cell surface 
receptors on platelets (14) and melanoma cells (la, 54). The 
initial approach to dissecting TS into functional domains used 
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umns such as heparin- and fibrinogen-Sepharose (7,  11,  12, 
47, 51). We produced a panel of  mAbs against both native and 
denatured TS with the hope of identifying antibodies that 
might react with specific domains and block the functions of 
TS mediated by these domains (19). 
A useful tool for characterizing the fragments of  TS as well 
as the complexes of TS with mAbs and its protein ligands is 
the electron microscope (19, 32). The native molecular mass 
of calcium-replete, trimeric TS is •450,000  D. The mass of 
the subunits, based on estimates from SDS gel electrophore- 
sis under reducing conditions, was in the range of 150,000- 
185,000 (36, 41). Recent sequencing of TS cDNA reveals that 
the true molecular mass of the subunit is somewhat less than 
these values, '~140,000  (see below). This is possibly due to 
the low isoelectric point of TS, '~4.7 (36), and the resulting 
low binding of SDS by the negatively charged protein. Fig. 
1 a  shows an image of a rotary-shadowed TS trimer in the 
presence of calcium. It is readily apparent that the protein 
is made up of regions of globular character as well as thin 
connecting strand segments. Fig. 1 b shows the model for TS 
structure that is consistent with all of the views of intact TS. 
Each subunit is represented as an asymmetric dumbbell con- 
sisting of a small globular domain, a connecting stalk, and 
a  larger globular domain  (19, 32).  In  the electron micro- 
graph, the small globules appear in the center close to one 
another, whereas the larger globular domains are splayed out 
around them. The only connection among the three subunits 
appears to be on the stalks at a point quite near the small 
globular domains. This method also reveals a profound con- 
formational change in TS upon the chelation of calcium ions 
by EDTA  (10, 32).  The large domains  appear to unravel, 
resulting in longer stalks and a reduction in the size of the 
large domains. 
This conformational change is also evident in the pattern 
of proteolytic cleavage of TS by a variety of proteases. We 
have used chymotrypsin most extensively (19), but other in- 
vestigators have obtained quite similar results with thrombin, 
trypsin, and plasmin (30, 31, 35). In the presence of calcium, 
the small domains are rapidly removed and the remaining 
large  peptide  is  nicked  about  100  amino  acids  from  the 
COOH terminus. The same cleavage occurs to liberate the 
small globular domain in EDTA, but the entire large globular 
domain is degraded resulting in a trimer of stalks each with 
a molecular mass of '~70 kD (10, 19, 31, 47). These proteo- 
lytic fragments are summarized in Fig.  2. 
The  small  globular  domain  has  been  identified  as  the 
heparin-binding  domain since  it binds  to heparin-agarose 
with the same affinity as TS itself. Our monoclonal antibody 
A2.5,  which immunoprecipitates the 25-kD heparin-bind- 
ing domain,  decorates the cluster of three small  globular 
domains  as  visualized  by  electron microscopy of rotary- 
shadowed TS-mAb complexes (19). Gartner et al.  (22) re- 
ported that polyclonal antibodies specific for the heparin- 
binding  domain  of bovine TS  could block the  secondary 
phase of platelet aggregation, thus implicating the heparin- 
binding domain in this function of TS.  Roberts et al.  (52) 
have  reported  that  TS  interacts  with  sulfatides  (sulfated 
glycolipids) via this heparin-binding domain and that hepa- 
rin and fucoidin are potent inhibitors of this binding activity, 
whereas chondroitin sulfate and hyaluronate are not. Lami- 
nin, von WiUebrand factor, and TS all bind sulfatides, but 
each has a  slightly different specificity (53).  The heparin- 
binding domain has been implicated in the hemagglutinating 
activity of TS (23, 24), and heparin is also a potent inhibitor 
of the binding of radiolabeled TS to human fibroblasts (44), 
suggesting  that  binding  to  these  cells  may  occur via  the 
heparin-binding domain. 
The stalk-like connecting region of each TS subunit con- 
tains a binding site for collagen. The trimer of stalks is read- 
ily purified by gel filtration of a chymotryptic digest of TS 
performed in EDTA (20).  Mumby et al.  first reported that 
TS binds specifically to collagen (47).  Their methods de- 
tected binding to type V, but not to other collagen types. This 
same group also found that a trimeric species composed of 
70-kD fragments cleaved from the TS chains by chymotryp- 
sin retained the ability to bind to type V collagen. We have 
examined the interaction of TS with pepsinized preparations 
of collagen types I through V using both direct, quantitative 
binding studies and electron microscopy of rotary-shadowed 
replicas of TS-collagen complexes (20). TS binds with low 
but significant affinity to all of these pepsinized collagens at 
a site at one end of the triple helical collagen monomer. The 
interaction with type V collagen is of much higher affinity 
Figure 1. (a) Electron micrograph 
taken by Dr. Nancy J. Galvin in 
the  author's laboratory  of a  ro- 
tary-shadowed  thrombospondin  tri- 
mer  in the presence of calcium 
(1 mM). Bar, 10 nm. (b) A model 
of the three subunits approximate- 
ly as they are arranged in the view 
of the trimer in a. Each subunit is 
one of the objects shaped like an 
asymmetric dumbbell. 
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Figure 2.  A model of the thrombospondin  subunit based on the 
results  of proteolysis,  affinity  chromatography,  high  sensitivity 
amino acid sequencing of fragments, and electron microscopy of 
rotary-shadowed thrombospondin-mAb complexes. A linear dia- 
gram of the peptide chain and its chymotryptic cleavage products 
in the presence and absence of calcium is shown in the bottom half 
of the figure. The ligand for each region of the subunit is indicated 
below the diagram. Ovals with arrows show the locations of the epi- 
topes  for the  indicated  monoclonal  antibodies  developed  in  the 
author's laboratory. Circles numbered  1, 2, and 3 indicate amino- 
terminal  sequences obtained for the proteolytic fragments shown. 
and stability and occurs at a site at the end of the pepsinized 
collagen molecule and at an additional site about two-thirds 
of the distance along the collagen triple helix from the lower 
affinity end site (20). The trimer composed of 70-kD chymo- 
tryptic peptides, which constitute the stalk region of TS, was 
also examined and found to bind to the same sites on all the 
collagen types as intact TS. A significant difference between 
the binding of intact TS and the trimer of stalks was found 
in the effect of calcium. Binding of intact TS was markedly 
lowered by increasing calcium levels from 10 pM to 1 mM, 
whereas the binding of the trimer of 70-kD fragments was 
completely insensitive to increasing calcium concentrations 
(20). This suggests that either the large globular domain in 
its calcium liganded state can interfere with the access of col- 
lagen molecules to their binding site on the stalk region of 
TS or that the globular state of the large domain exerts an 
indirect or conformational influence on the collagen-binding 
site. 
TS also binds to fibronectin (29, 31), fibrinogen (11, 29, 31), 
plasminogen  (31, 59),  and  laminin  (31).  The dissociation 
constants for the binding of TS to all of these proteins is in 
the range of 40 to 150 nM. Lawler et al. (31) have investigated 
the binding of the isolated trimer of 70-kD  fragments de- 
scribed above to these proteins immobilized on plastic wells 
and found that the 70-kD stalk region also appears to contain 
the binding sites for fibrinogen,  fibronectin, plasminogen, 
and  laminin.  Sequencing  studies  (below)  reveal  that  this 
70-kD region is composed of at least four distinct regions of 
protein structure.  Thus, some or all of these proteins could 
have distinct binding sites within the stalk region of TS. 
The model for the structure of the TS subunit that emerged 
from the summation of these studies mentioned above along 
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Figure 3. Schematic representation of the amino acid sequence of 
the thrombospondin peptide chain of 1,170 amino acids. For scale, 
note that the heparin-binding domain, region B, is 240 amino acids 
long. Numbers above the bar indicate the number of disulfide bonds 
in each segment; arrows above mark known peptide sequences used 
to confirm and align the nucleotide sequence.  The extreme NH2- 
and COOH-terminal disulfide bonds are indicated as such above the 
bar.  Filled  arrowheads  below  mark  potential  N  glycosylation 
sites and the two S's below show the proposed interchain disulfide 
crosslinking sites contained within region C. The locations of the 
RGDA sequence and the free sulfhydryl are shown below the bar. 
The vertical  dashed line  in region  H is the  site of chymotryptic 
cleavage of the COOH-terminal  fragment which contains the epi- 
tope for the platelet aggregation blocking mAb C6.7. 
with the results of microsequencing of the isolated domains 
(19) is  shown in Fig.  2.  A  primary conclusion is that the 
subunit of TS is a colinear representation of the polypeptide 
chain, another hallmark of modular proteins like fibronectin. 
This allows for evolution by addition or deletion of exons 
without perturbing the structure of adjacent regions of the 
protein. 
Amino Acid Sequence of Thrombospondin 
from cDNA Clones 
The complete amino acid sequence of TS allows one to think 
in more precise terms about the structures of the'IS domains, 
and also defines for the first time several interesting regions 
of TS  structure.  We have determined the complete amino 
acid sequence of human TS from cDNA clones isolated from 
a human fibroblast library. We first isolated a clone desig- 
nated 6A that encodes the heparin-binding domain and part 
of the collagen-binding domain of TS (15).  This clone was 
isolated by screening  the human  fibroblast cDNA library 
with degenerate synthetic oligonucleotides based on the se- 
quence of TS tryptic peptides. The nucleotide sequence was 
confirmed as being that of TS since it predicted the amino 
acid sequences of six TS peptides including those found at 
the  NH2  terminus  of  the  mature  peptide  chain  and  the 
collagen-binding  domain.  Using  radiolabeled  restriction 
fragments from 6A, we rescreened the human fibroblast li- 
brary and recovered two cDNAs each •4.2-kb  long. One of 
these has been sequenced in its entirety and contains an open 
reading frame of 3,510  nucleotides encoding the entire TS 
peptide chain. 
Fig.  3  summarizes  the  information  contained  in  the 
deduced amino acid sequence of TS. Each subunit is com- 
posed of 1,152 amino acids plus an 18-residue signal peptide. 
This amino acid sequence translated from the cDNA con- 
rains all of the remaining TS peptides that we had sequenced 
previously and confirms the order of the domains originally 
proposed based on limited amino acid  sequence data (19) 
(Fig.  2).  Using  our protein  sequence  data to confirm the 
identity of the clones, Lawler and Hynes (33) cloned a series 
Frazier Thrombospondin  627 of overlapping cDNAs from a human endothelial cell library 
with antibody selection. This composite sequence is identi- 
cal to the one we have obtained except at one nucleotide, 
which results in amino acid number 66 being an alanine resi- 
due in the fibroblast sequence and a threonine residue in 
the endothelial sequence.  Kobayashi et al.  (28)  have also 
reported the sequence of the first 379 amino acids of human 
umbilical vein TS, and their sequence is identical with our 
fibroblast sequence. Northern analysis indicates an mRNA 
size for TS of over 6 kb (15, 28,  33). Preliminary Southern 
blotting experiments are consistent with there being only one 
TS gene (15). However, more thorough analysis will be re- 
quired to determine this number with certainty. 
The amino acid sequence of TS reveals several striking 
features that help to explain the previously deduced proper- 
ties of  the molecule. The most fascinating aspect of  the struc- 
ture is that it has obviously been assembled from a variety 
of ancestral precursors presumably by "exon shuffling" This 
is particularly evident in the stalk-like, central portion of the 
peptide chain, which is extremely rich in cysteine (Fig. 3), 
all of which, with one exception, are presumably involved 
in disulfide bonds. Given the modular nature of this region, 
it is quite likely that the disulfide bonds are limited to pairing 
within each region rather than introducing the complications 
of maintaining intersegment (probably inter-exon) connec- 
tions during evolution. This notion is made more tenable be- 
cause the majority of the cysteines align with those in homol- 
ogous proteins (15, 28, 33). In contrast to regions D through 
G, the amino-terminal heparin-binding domain (region B) 
and the COOH-terminal cell (platelet) adhesion domain (re- 
gion H) are unique in that they show no significant homology 
with other' proteins. Each region contains only a single in- 
tradomain disulfide bond, consistent in both cases with our 
previous observations (12, 14). 
The heparin-binding domain is followed by the sequence 
that  we  had  determined  for  the  NH2  terminus  of  the 
collagen-binding domain or stalk region of TS (19, 20). The 
stalk begins with region C, which contains only 21 amino 
acids and two cysteines, which are probably involved in the 
intersubunit disulfide bonds.  The sequence is  C-G-I-S-C, 
and  this  spacing  of the cysteines also occurs in all  three 
fibrinogen chains at both sites at which disulfides connect the 
three chains (48).  Note that to form a  symmetric trimeric 
structure each peptide chain must contribute at least two cys- 
teines. Region D is composed of  97 residues including 10 cys- 
teines, all of which align with cysteine residues in the NH2- 
terminal propeptide of alpha-(1)-I human procollagen (6). In 
fact this part of TS is 35 % identical with exon 50 of the hu- 
man type I collagen and appears to represent the precise in- 
corporation of a progenitor of exon 50 into the ancestral TS 
gene.  Exon  51,  which  encodes  the  signal  peptide  of the 
procollagen, is also represented at the NH2 terminus of re- 
gion D, but the homology is somewhat less striking. All 10 
of the cysteine residues in the type I collagen NH2-terminal 
propeptide are intrachain, paired within the propeptide (49). 
Since all 10 of these cysteines are conserved in TS, we sug- 
gest that they form five intrasegment disulfide bonds. 
Recently it has been demonstrated that the purified NH2 
terminal propeptide of type I collagen can inhibit the synthe- 
sis of procollagen in fibroblasts by lowering the levels of type 
I  procollagen mRNA  (66).  Perhaps this region of TS has 
functions other than collagen binding related to regulation of 
gene expression. In this vein, it has been noted that the addi- 
tion of TS to the medium of smooth muscle cells causes an 
enhanced sensitivity to epidermal growth factor (EGF) stim- 
ulation and this effect was blocked by heparin (40). An auto- 
crine role for TS synthesized by these cells was proposed in 
which TS and heparin modulate the growth of smooth muscle 
cells.  In  turn,  it  has  been  reported  that  platelet-derived 
growth factor rapidly stimulates the synthesis of TS (39) by 
smooth muscle cells by increasing the level of TS mRNA 
(28).  Thus stimulation of smooth muscle ceils by platelet- 
derived growth factor from platelets could have the effect of 
making them more sensitive to EGE 
The remainder of the stalk region is made up of two differ- 
ent threefold repeated segments. Region E consists of three 
repeats of ~60 residues, each homologous with one another 
and with a region of a malaria circumsporozoite protein. Re- 
gion  F  is  a  threefold  repeated  segment,  again  of  *60 
residues,  homologous to  regions h,  i,  and j  of the  EGF 
precursor (16). Lawler and Hynes (33) have designated these 
type I and type II TS repeats. Both types of segments have 
six cysteine residues within ~60 amino acids.  Particularly 
for the EGF-related segments, it is likely that the disulfide 
pairing pattern is contained within each 60 residue segment. 
All of the 18 cysteines align with those in the EGF precursor, 
allowing  for  one  insertion  that  would  not  interrupt  the 
disulfide bonding pattern. Hence the EGF structure is proba- 
bly a good model for this part of the stalk, and these "growth 
factor" repeats would be consistent with the average thick- 
ness of the stalks calculated to be ,~1.5 nm. It should be em- 
phasized that the overall identity with the EGF repeats is on 
the order of 25 %, so that it is very unlikely that TS retains 
any ability to interact with the EGF or related receptors. 
The type I repeats of region E are interesting considering 
previous information regarding the possible involvement of 
TS in the pathogenesis of malaria (55). The sequencds in re- 
gion E of TS exhibit homology with a segment of the circum- 
sporozoite protein designated region II (8).  In contrast to 
most regions of this highly variable protein, region II is well 
conserved among all species of malaria for which sequence 
data are available. In the area of greatest similarity with TS, 
15 of 17 continuous residues are identical and these overlap 
with the 13 residues of region II in the malaria protein. The 
sporozoite is the initial infective stage of malaria, which is 
introduced into the bloodstream from the mosquito salivary 
gland,  and homes to and colonizes the liver.  From here, 
merozoites are liberated and infect erythrocytes. These in- 
fected red cells are sequestered along venular endothelium, 
thus removing them from the circulation. In this later seques- 
tration event TS-mediated adherence was proposed to play a 
role (55). An interesting hypothesis emerges from these con- 
siderations.  If region II is actually the determinant on the 
sporozoite that is recognized by liver ceils, then the receptor 
in liver may be designed to bind TS by recognizing its type 
E repeats. If this were in fact the case, it would represent an- 
other instance of the appropriation of a host recognition sys- 
tem by a parasite to gain entry, in this case, to the liver. Using 
synthetic peptides based on the malaria-like sequences we 
are currently testing this hypothesis. However, at present, the 
homology between the type E repeats of TS and the circum- 
sporozoite protein region II does not help to explain the pro- 
posed involvement of TS in the sequestration event. The data 
suggest that the parasitized red cells should express a protein 
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liver receptor. 
Region G of the TS sequence is readily identified as the 
primary calcium-binding domain. Electron microscopy (10, 
32), proteolysis (10, 20, 30-32, 34) and monoclonal antibod- 
ies that recognize this region of the structure (10) all suggest 
that it is compact in the presence of calcium and becomes 
extended or loosened when calcium is removed. This do- 
main provides the  most interesting challenge in terms of 
deducing a  testable model for its  structure.  Four calcium 
binding  sites per subunit have been detected with optical 
methods and proteolysis (34)  and these have dissociation 
constants  in the range of 50--120 gM.  We have used two 
mAbs that recognize epitopes whose exposure is modulated 
by calcium concentration to detect conformational transi- 
tions in TS (10). One of these, A6.1, binds over a broad range 
of calcium concentrations probably reflecting a number of 
calcium-binding  sites  with  dissociation  constants  ranging 
from above 100 IxM to less than 1 IxM. The other mAb, D4.6, 
detects a conformational change in TS which is coupled to 
an extremely tight binding site or sites with a dissociation 
constant below 100 nM (10). Thus there probably exist in TS 
several (five or more per subunit) calcium-binding sites that 
exhibit a broad range of affinities and should have differing, 
but perhaps related structures. 
Region G of TS consists of seven highly conserved repeats 
of 23 amino acids containing two cysteine residues, one near 
each end. In some cases, this unit is separated by up to 15 
amino acids from its next repeat by a segment of variable 
length that is related to the 23 amino acid segment. If the 
highly conserved 23 residue segments are called A and the 
less well conserved, but still related, intervening segments 
of variable length called B, then the overall structure of this 
region is B (A) A B A A B A A B A B A B (A). Partial repeats 
of the A  structure are  in parentheses.  The concensus se- 
quences of the A  and B segments are 
DNC(P)hhxNx(D)QxD(OH)DxDGx G DxC  (Arepeat) 
xxD  x  DxDGx(P) Bxx  (Brepeat), 
where the capital  letters are the  single letter code for an 
amino  acid,  which always occurs at that position,  paren- 
theses indicate a strong preference for the amino acid (OH 
stands for thr, ser, or tyr), the h represents any hydrophobic 
residue, and x means no obvious preference in that position. 
The B repeats are obviously related to the A structures and 
may have been derived from a common evolutionary precur- 
sor. It is clear that this region has been built up through a 
series of duplication and deletion events, and the degree of 
relatedness among specific A and B repeats implies a very 
complex pathway of  evolution. The degree of  overt homology 
between region G  of TS and calcium-binding proteins like 
calmodulin is extremely small, limited to the spacing of the 
acidic,  presumably  calcium-binding,  residues.  If TS  and 
calmodulin are derived from a common ancestor, the diver- 
gence must have occurred very long ago. 
A major difference between these putative calcium-bind- 
ing sites of TS and those of the intracellular calcium-binding 
proteins is the presence of the cysteine residues. In calmodu- 
lin, for example, the calcium-binding residues are bounded 
by the E and F helices, which both stabilize and participate 
in the binding of calcium and form the so-called "E-F hand" 
structure (2). Given the locations of the cysteines in TS, it 
is  reasonable to  suggest that the  calcium-binding loop is 
closed and constrained by disulfide bonds formed between 
the cysteines at the beginning and end of each type A  seg- 
ment. A direct test of whether the type A elements can bind 
calcium and if the binding is affected by the presence or ab- 
sence of a disulfide closure of the loop is being conducted 
using synthetic peptides representing several of the type A 
sequences from "IS. If these type A repeats bind calcium in 
the closed disulfide bonded loop form, this would suggest 
that the correct model for the disulfide connectivity of this 
region is that which allows only pairing within each type A 
structure. This model is also consistent with the observed ex- 
tensibility of this region since the type B segments can pro- 
vide more than enough peptide chain to account for the ap- 
parent increase in length when calcium is removed (10, 32). 
It is as though this region of 'IS provides a way of varying 
the length of the connecting region between the binding do- 
mains for heparin and collagen at the NH2 terminus of the 
subunit and those for platelets and cells at the COOH ter- 
minus. 
Given the wide participation of the RGD (Arg-Gly-Asp) 
sequence in cell-matrix interactions (56), it was of great in- 
terest to determine whether TS contained a potentially active 
RGD sequence somewhere within its structure. In fact one 
RGDA tetrapeptide, an active analogue of RGDS, is found 
at the very end of the calcium-binding domain (Fig. 3). An 
RGDA sequence exists in the slime mold lectin Discoidin I 
where it is bound by a receptor on the surface of aggregating 
Dictyostelium cells (18). Despite the existence of this RGDA 
sequence in TS, accumulating evidence has failed to impli- 
cate RGD recognition in TS function. This may be for two 
reasons. First, the RGDA sequence in TS is immediately fol- 
lowed by a cysteine residue that is almost certainly disulfide 
bonded  to  another.  If the  above model  for the  calcium- 
binding domain is correct, the RGDA sequence would be 
contained within a putative calcium-binding loop. Thus in- 
terference from the disulfide bond may prevent the binding 
of the RGDA sequence to any of the receptors that can bind 
it. 
An alternative possibility, and one that is perhaps more in- 
teresting in light of the large effects of calcium on this region 
of the TS structure, is that the exposure of the RGDA se- 
quence is regulated by the number of calcium ions bound to 
TS.  Since the  RGDA  occurs within a  proposed calcium- 
binding loop, the presence of the bound ion could block the 
ability of the sequence to interact with a receptor. If such a 
mechanism were at work in TS, one must then ask what rele- 
vance this might have to TS function. Being a matrix glyco- 
protein, TS is synthesized and perhaps cosecreted with other 
matrix components from vesicles. These intracellular com- 
partments would provide an environment in which the cal- 
cium concentration could be closely regulated. This may be 
important for the proper folding of the protein. Furthermore, 
if RGD receptors were also being synthesized by the same 
cell, these would be inserted into the membranes of vesicles 
with their binding domains facing the lumen where soluble 
components containing RGD sequences could be bound. In 
this type of scenario it is easy to imagine that regulation of 
calcium levels could have the effect of controlling the extent 
or the order in which TS and perhaps other matrix compo- 
nents, many of which bind calcium, would be brought into 
juxtaposition and assembled. A further consideration is that 
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access from the circulation is limited, thus resulting in lower 
than "physiological" ambient calcium concentrations. This 
effect of sequestration  could  be  augmented  by  the  high 
calcium-binding capacity of many matrix constituents such 
as proteoglycans and glycosaminoglycans. In this way local 
calcium  levels could vary considerably with concomitant 
effects on TS functions such as collagen binding (20). 
Finally, the extreme COOH-terminal portion of TS, which 
is proposed to have a role in platelet function and cell adhe- 
sion, appears to be unique in structure.  Only two cysteine 
residues exist in this domain and our previous studies indi- 
cate that the one nearest the COOH terminus of TS must be 
paired with a Cys upstream of the chymotryptic cleavage site 
(Fig. 3, dashed line).  The removal of this COOH-terminal 
chymotryptic fragment from the rest of TS requires both 
denaturation  and  reduction  (14). Thus  the  most  COOH- 
terminal cysteine of TS could be paired with either the last 
one in the calcium-binding domain (which occurs in the last 
partial type A repeat and its partner is absent), or the first 
and only other one in the COOH-terminal domain. The one 
of these two cysteines that remained unpaired would then 
presumably be the one identified by Danishefsky et al.  (9) 
as the free sulfhydryl group of TS. To resolve this question, 
D. E  Mosher and K. Skorstengaard (personal communica- 
tion) treated intact TS with radiolabeled iodoacetic acid in 
8 M urea, then digested the labeled TS and isolated the pep- 
tide bearing the label. Sequence analysis indicated that the 
alkylated Cys residue is number 974 in the TS sequence, or 
the one that occurs at the beginning of the COOH-terminal 
domain. Thus, barring disulfide exchange, it appears that the 
most COOH terminal cysteine of TS is paired to the last Cys 
of the calcium-binding domain, which occurs in its last im- 
perfect type A repeat. 
Prospects 
The  amino  acid  sequence of TS  has  already  provided  a 
wealth of new ideas and speculations about how TS accom- 
plishes its known functions and has even suggested new func- 
tions for TS. Further, the availability of cDNA clones to be 
used as probes for cloning TS genes will lead to the descrip- 
tion  of an  undoubtedly complex intron-exon structure as 
well as the 5' transcriptional regulatory region of the gene. 
There are already some tantalizing hints of the kinds of sig- 
nals  that  regulate  TS  gene  expression,  such  as  platelet- 
derived growth factor, which causes a very rapid increase in 
levels ofTS mRNA and subsequent synthesis in smooth mus- 
cle cells (28,  39). The release of TS from the cell matrix by 
heparin  suggests  another mode of rapid  regulation of TS 
function (39). The rapidity with which TS levels or locations 
are altered in these systems as well as in the case of secretion 
by activated platelets may indicate that it has a function even 
in nonplatelet sites, which necessitates its rapid modulation. 
This idea is further supported by binding studies using iodi- 
nated TS that found that it binds to fibroblasts and is rapidly 
internalized and degraded in contrast to fibronectin, which 
is slowly incorporated into the matrix (44). As yet it is un- 
clear just what this function might be,  although from this 
early work it seems as though a role in regulation of gene 
expression through rapid alteration of the properties of the 
extracellular matrix is not an unreasonable suggestion. An- 
other area that needs to be addressed is the possible role of 
TS in development,  since it is  now abundantly clear that 
other adhesive glycoproteins function in a highly regulated 
fashion in cell adhesion and in the cell migrations that form 
tissues and organs. (17). Another use of the cDNA will be in 
expressing first, the major domains of TS, and then selec- 
tively altered or mutagenized pieces of the protein. Tests of 
the in vivo functions of TS will require the use of transgenic 
animals, particularly to explore the role of TS in hemostasis. 
Despite our ever widening knowledge about the distribu- 
tion of TS in a variety of tissues and cells, several factors fo- 
cus our attention on the role of TS in hemostasis. Not only 
is TS the most prevalent protein in platelet alpha-granules (4, 
36) and involved in platelet aggregation (14, 22, 37),  but it 
is implicated in processes like smooth muscle cell prolifera- 
tion (39, 40) and perhaps wound healing. The finding that TS 
becomes incorporated, perhaps transiently, into blood clots 
(5) is also intriguing and may be related to the role of the clot 
as a specialized matrix that can promote the healing process 
as well as halt bleeding. Much remains to be learned about 
the possible involvement of TS in atherosclerosis (64). Ther- 
apies that rely on targeting plasminogen activators to sites of 
clot formation currently focus on the unique localization of 
fibrin in the clot. However, TS in clots may present another 
site to which therapeutic agents can be targeted. The ability 
of TS to bind plasminogen may also be of relevance here (31, 
59, 60). The next few years should provide us with answers 
to many of the questions raised here and will raise intrigu- 
ing new ones as the functions of this interesting protein are 
explored. 
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